Loading page…
Find your medicineSearch name, salt, strength or type
Eli Lilly is a pharmaceutical manufacturer known for medicines including Mounjaro and Zepbound, both containing the active ingredient tirzepatide.
Eli Lilly and Company is the manufacturer associated with Mounjaro and Zepbound. Both medicines contain tirzepatide but have different approved indications. Mounjaro is primarily associated with the treatment of type 2 diabetes, while Zepbound is indicated for chronic weight management in eligible adults and for certain adults with obesity and moderate-to-severe obstructive sleep apnea.
Eli Lilly provides prescribing information, medication guides, instructions for use, and safety information for its medicines. Patients should use Mounjaro or Zepbound only according to the prescribing information and directions provided by their healthcare professional.If you're unsure about your prescription, contact our support team for guidance on next steps.
Diabetes Management - Mounjaro belongs to the category of prescription medicines used in the management of type 2 diabetes. It works through activation of both GIP and GLP-1 receptors and is used together with diet and exercise to improve blood glucose levels.
Weight Management - Zepbound is a prescription medicine used for chronic weight management in eligible adults. It is used together with a reduced-calorie diet and increased physical activity and contains tirzepatide as its active ingredient.
Obstructive Sleep Apnea and Obesity - Zepbound is also approved for adults with obesity and moderate-to-severe obstructive sleep apnea. Its use for this indication is part of its approved prescription use and should be guided by a healthcare professional.
Mounjaro and Zepbound should not be considered interchangeable simply because both contain tirzepatide. Their approved uses may differ, and the appropriate medicine dosage depends on the patient's medical condition, treatment goals, medical history, and applicable prescribing information. A healthcare professional should determine whether either medicine is appropriate. Patients should also check the medicine name, strength, packaging, and prescription information before use.
Mounjaro and Zepbound are prescription medicines and should be used under the guidance of a qualified healthcare professional. Zepbound should not be used together with other tirzepatide-containing products or GLP-1 receptor agonist medicines. It also carries important warnings, including a boxed warning concerning thyroid C-cell tumors, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or by people with Multiple Endocrine Neoplasia syndrome type 2.
Patients should read the prescribing information and medication guide supplied with their medicine before use. Any questions about dosage, missed doses, side effects, interactions, contraindications, or whether Mounjaro or Zepbound is appropriate should be discussed with a healthcare professional or else you can also connect with our support team for further help.
Tirzepatide
Both contain tirzepatide, but they have different approved indications. Mounjaro is used for type 2 diabetes and has additional cardiovascular-risk-reduction approval in the United States, while Zepbound is approved for chronic weight management in eligible adults and for certain adults with obesity and moderate-to-severe obstructive sleep apnea.